Please login to the form below
enadenotucirev
This page shows the latest enadenotucirev news and features for those working in and with pharma, biotech and healthcare.
Bristol-Myers Squibb acquires Cormorant for $520m
That project will look at the safety and efficacy of enadenotucirev - which is made by PsiOxus Therapeutics in Oxford, UK - in combination with Opdivo for the treatment of a range of
Latest news
-
BMS to explore new options for its immuno-oncology drug Opdivo
Enadenotucirev is designed to have immune stimulating effects and the companies hope that combining it with Opdivo, which alleviates immune suppression, will improve tumour shrinkage and treatment durability. ... BMS has then reserved the rights to first
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- BMS eyes approval for second Opdivo combo in kidney cancer
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
